X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Average Rating of "Moderate Buy" from AnalystsMarket Beat·Jul 25 at 03:29 AMXFOR-0.25%
Wall Street analyst calls: DA Davidson starts AGCO at buy; Citi cuts Pepsi to neutral; Wells Fargo upgrades SeagateCoinLive·Jul 10 at 07:33 AMMLCO+0.36%AGCO+2.89%
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Unusual Whales·Jul 7 at 03:32 PMXFOR-0.25%
X4 Pharmaceuticals issues inducement stock options for 750,000 shares at $4.03 eachPUBT·Jul 7 at 03:30 PMXFOR-0.25%
X4 Pharmaceuticals appoints CAMP4 CFO Kelly Gold to board, audit committeePUBT·Jul 1 at 06:01 AMXFOR-0.25%CAMP0.00%
X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update | XFOR Stock NewsStockTitan·May 5 at 10:15 PMXFOR-0.25%FBT+1.85%
13:41 ETNorgine anuncia la autorización de comercialización de la Comisión Europea para XOLREMDI® (mavorixafor)prnewswire·Apr 29 at 12:42 PMXFOR-0.25%
